American Society of Clinical Oncology Annual Meeting
The American Society of Clinical Oncology (ASCO) will host its annual meeting June 1-5, 2018, in Chicago, Illinois. The meeting will bring together more than 32,000 oncology professionals to discuss new treatments and ongoing controversies, following the theme of “Delivery Discoveries: Expanding the Reach of Precision Medicine.” Sign up for our daily email blasts on our registration page, and check back here during the conference for full coverage.
Dr Sara M. Tolaney on Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast Cancer
August 08, 2018
Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses challenges with managing patients with HER2-positive breast cancer and how clinical trials provide another treatment approach for these patients.
August 06, 2018
Organizations are trying to think about how they can involve team-based care by incorporating individuals who have a certain skill set that can relieve the practicing clinician, physician, nurse practitioner, or physician assistant from some of the burden, explained Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University.
July 27, 2018
Individuals, families, and local, state, and federal government all have incurred costs as a result of the opioid epidemic, explained Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University.
July 25, 2018
We know that there are a lot of problems with precision medicine and lots of areas that we need to define better, but that shouldn’t stop us from moving forward and trying to optimize the care for our patients, said Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare.
July 23, 2018
Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, outlines the role of adjuvant therapy in treating patients with HER2-positive breast cancer, as well as the absence of biomarkers in this patient population.
July 18, 2018
We need to bring together our real-world data and our reimbursement systems to recognize the fact that a lot of what could be gained by precision medicine is going to be based on a lot of research, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.
July 08, 2018
There are small subgroups within each tumor type and within each molecular type, and someday, we might be able to actually pair the 2 to give patients a little bit more personalization and precision to their treatments, said Victoria Villaflor, MD, associate professor of Medicine, hematology and oncology.
July 06, 2018
Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center, discusses the shift toward interoperability among electronic health record systems and efforts needed to accelerate this shift.
July 05, 2018
Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, discusses challenges associated with conducting precision medicine trials in the community setting.
July 02, 2018
It’s been years since a large portion of colon cancer patients have seen any innovations in treatment. However, there are dietary and physical behavioral changes individuals can make that positively impact colon cancer survival said Leonard Saltz, MD, executive director of Clinical Value and Sustainability, head of Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center.